United States - English - NLM (National Library of Medicine)

fresenius medical care holdings, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - ferric cation 20 mg in 1 ml - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and

United States - English - NLM (National Library of Medicine)

american regent, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - ferric cation 20 mg in 1 ml - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer. risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and

United States - English - NLM (National Library of Medicine)

martin ekwealor pharmaceuticals, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - ferric cation 150 mg - prevention and treatment of iron deficiency and/or other nutritional megaloblastic anemias myferon 150 is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias. myferon 150 is contraindicated in patients with a known hypersensitivity to any of the components of this product. hemochromatosis and hemosiderosis are contraindications to iron therapy.

United States - English - NLM (National Library of Medicine)

martin ekwealor pharmaceuticals, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - myferon 150 forte is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias. myferon 150 forte is contraindicated in patients with a known hypersensitivity to any of the components of this product. hemochromatosis and hemosiderosis are contraindications to iron therapy.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer. risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and

United States - English - NLM (National Library of Medicine)

american regent, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer. risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) .   animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects a

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). known hypersensitivity to venofer. 8.1 pregnancy risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data). available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations). animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth de

United States - English - NLM (National Library of Medicine)

wh nutritionals, llc - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611), heme iron polypeptide (unii: 31vdo12cjy) (ferrous cation - unii:gw89581owr) - folic acid 1 mg - ​hemetab is a prescription iron supplement indicated for use in improving the nutritional status of iron deficiency. this product is contraindicated in patients with known hypersensitivity to any of the ingredients. this product is also contraindicated in patients with hemochromatosis and hemosiderosis.

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - iron sucrose (unii: fz7nyf5n8l) (iron sucrose - unii:fz7nyf5n8l) - iron sucrose 497.5 g in 500 g

United States - English - NLM (National Library of Medicine)

coopersurgical, inc. - ferric subsulfate (unii: 3qj8ws6v8h) (ferric cation - unii:91o4lml611) - ferric cation 259 mg in 1 g - ferric subsulfate, aqueous, is a stypic agent used for achieving local hemostasis. in punch biopsies of the full dermis, the time to achieve hemostasis is typically less than 20 seconds.1 one method of applying ferric subsulfate solution for dermal use consists of the physician placing fingers at the opposite edge of the wound and stretching the skin. the wound is then wiped with gauze, the ferric subsulfate solution applied, and the tension maintained for approximately 15 seconds. 2